

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 August 2007 (30.08.2007)

PCT

(10) International Publication Number  
WO 2007/096618 A2

(51) International Patent Classification: Not classified

(21) International Application Number:  
PCT/GB2007/000608

(22) International Filing Date:  
21 February 2007 (21.02.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0603455.7 21 February 2006 (21.02.2006) GB

(71) Applicant (for all designated States except US): **CANCER RESEARCH TECHNOLOGY LIMITED** [GB/GB]; Sardinia House, Sardinia Street, London, Greater London WC2A 3NL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BROWN, Robert** [GB/GB]; Centre for Oncology and Applied Pharmacology, University Of Glasgow, Cancer Research Uk Beatson Laboratories, Garscube Estate, Glasgow, Strathclyde G61 1BD (GB). **PLUMB, Jane** [GB/GB]; Centre for Oncology and Applied Pharmacology, University Of Glasgow, Cancer Research Uk Beatson Laboratories, Garscube Estate, Glasgow, Strathclyde G61 1BD (GB). **AHERNE, Gladys, Wynne** [GB/GB]; The Institute of Cancer Research, Cancer Research Uk Centre For Cancer Therapeutics, Cruk



Laboratories, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG (GB). **MCDONALD, Edward** [GB/GB]; The Institute of Cancer Research, Cancer Research Uk Centre For Cancer Therapeutics, Cruk Laboratories, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG (GB). **JONES, Keith** [GB/GB]; The Institute of Cancer Research, Cancer Research Uk Centre For Cancer Therapeutics, Cruk Laboratories, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG (GB). **HILTON, Stephen** [GB/GB]; The Institute of Cancer Research, Cancer Research Uk Centre For Cancer Therapeutics, Cruk Laboratories, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG (GB).

(74) Agents: **WYTENBURG, Wilhelmus** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE



(57) Abstract: The present invention pertains to certain 2-[3H-thiazol-2-ylidinemethyl]pyridine compounds and analogs thereof, which, *inter alia*, inhibit cell proliferation, treat cancer, etc., and more specifically to compounds of the following formula, wherein R<sup>A1</sup>, R<sup>A2</sup>, R<sup>A3</sup>, R<sup>A4</sup>, R<sup>B1</sup>, R<sup>B2</sup>, RNA, RNB, and X- are as defined herein. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both *in vitro* and *in vivo*, to inhibit cell proliferation, and in the treatment of proliferative conditions such as cancer, etc.

WO 2007/096618 A2